Clinical trial
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
NCT00141323 · Ligand Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00141323 |
|---|---|
| Title | Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) |
| Official title | PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene |
| Acronym | PEARL |
| Lead sponsor | Ligand Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug, Other |
| Interventions | lasofoxifene, placebo |
| Enrollment | 8,556 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 1, 2005 |
| Last update posted | Aug 15, 2011 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Costa Rica, Croatia, Denmark, Egypt, Estonia, Finland, France and 20 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: